Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

[1]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Tinelli,et al.  Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Swann,et al.  Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers , 2010, Clinical Cancer Research.

[5]  B. Monk,et al.  Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Gilbertson,et al.  Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jeffrey W. Clark,et al.  Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. , 2010, The oncologist.

[8]  F. Fostira,et al.  Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting. , 2010 .

[9]  G. Sledge,et al.  Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). , 2010 .

[10]  R. Gray,et al.  A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). , 2010 .

[11]  P. Hegde,et al.  Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies. , 2010 .

[12]  P. Hegde,et al.  Biomarkers of treatment benefit in a randomized phase II study of bevacizumab in combination with carboplatin and paclitaxel in metastatic melanoma patients (BEAM). , 2010 .

[13]  E. Perez,et al.  Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). , 2010 .

[14]  Anwar R. Padhani,et al.  Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  M. Maitland,et al.  Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors , 2010, Journal of the National Cancer Institute.

[16]  A. Ravaud,et al.  Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Small,et al.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Gómez-Pinillos,et al.  Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. , 2010, Cancer investigation.

[19]  I. Brandslund,et al.  The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. , 2010, Gynecologic oncology.

[20]  A. Harris,et al.  Vascular Biology , Atherosclerosis and Endothelium Biolog y Expression of Vascular Notch Ligand Delta-Like 4 and Inflammatory Markers in Breast Cancer , 2010 .

[21]  M. Frosch,et al.  Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Schiller,et al.  Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Jeffrey S. Morris,et al.  Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Moore,et al.  Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Curley,et al.  Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. , 2009, JAMA.

[26]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Harris,et al.  Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis , 2009, Journal of cellular and molecular medicine.

[28]  Jeffrey W. Clark,et al.  Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. , 2009, Cancer research.

[29]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Perez,et al.  5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) , 2009 .

[31]  H. Hurwitz,et al.  Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression , 2009, Hypertension.

[32]  J. Xie,et al.  Endothelial-specific expression of WNK1 kinase is essential for angiogenesis and heart development in mice. , 2009, The American journal of pathology.

[33]  Jeffrey W. Clark,et al.  Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Jesberger,et al.  A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers , 2009, Clinical Cancer Research.

[35]  Y. Meng,et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.

[36]  Y. Meng,et al.  Characterization and Regulation of Bv8 in Human Blood Cells , 2009, Clinical Cancer Research.

[37]  R. Ramlau,et al.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Dancey,et al.  Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. , 2009, The Lancet. Oncology.

[39]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. Miles,et al.  Efficacy of bevacizumab (BV) plus docetaxel (D) does not correlate with hypertension (HTN) or G-CSF use in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) in the AVADO phase III study. , 2009 .

[41]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[42]  Jerry Younger,et al.  VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy , 2008, Clinical Cancer Research.

[43]  D. Sargent,et al.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  E. Small,et al.  Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Oza,et al.  Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab , 2008, Clinical Cancer Research.

[46]  H. Joensuu,et al.  Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Gregory Karczmar,et al.  Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. Perez,et al.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Thomas D. Wu,et al.  Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer , 2008, Clinical Cancer Research.

[50]  R. Kerbel,et al.  Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. , 2008, Cancer cell.

[51]  W. Oyen,et al.  Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. , 2008, European journal of cancer.

[52]  L. Borsu,et al.  WNK1 haplotypes and bevacizumab-induced hypertension , 2008 .

[53]  B. Lévy,et al.  Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  T. Gruenberger,et al.  Neoadjuvant Treatment of Colorectal Cancer with Bevacizumab: The Perioperative Angiogenic Balance Is Sensitive to Systemic Thrombospondin-1 Levels , 2008, Clinical Cancer Research.

[56]  R. Gray,et al.  Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study , 2008, Clinical Cancer Research.

[57]  Mallika Singh,et al.  Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression , 2008, Proceedings of the National Academy of Sciences.

[58]  Rene Bruno,et al.  Clinical pharmacokinetics of bevacizumab in patients with solid tumors , 2008, Cancer Chemotherapy and Pharmacology.

[59]  Daniel J Sargent,et al.  Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Yiting Cao,et al.  Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[62]  F. Peale,et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.

[63]  Wen Shi,et al.  Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. , 2007, Cancer research.

[64]  Wei Chen,et al.  Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  S. Steinberg,et al.  Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. , 2007, Radiology.

[66]  F. Kabbinavar,et al.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.

[67]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[68]  R. Kerbel,et al.  Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  W. Berdel,et al.  Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity , 2007, Leukemia.

[70]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.

[71]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[72]  A. Goldhirsch,et al.  Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. , 2006, Blood.

[73]  Kevin Camphausen,et al.  Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  A. Jubb,et al.  Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  A. Jubb,et al.  Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. , 2005, Journal of the National Cancer Institute.

[76]  E. Vokes,et al.  Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G) , 2005 .

[77]  M. Sirois,et al.  Vascular Endothelial Growth Factor (VEGF)-A165-induced Prostacyclin Synthesis Requires the Activation of VEGF Receptor-1 and -2 Heterodimer* , 2005, Journal of Biological Chemistry.

[78]  Napoleone Ferrara,et al.  Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. , 2005, Cancer research.

[79]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[81]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[82]  D. Hanahan,et al.  Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. , 2003, Cancer cell.

[83]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[84]  Stephen B Fox,et al.  The angiogenic switch for vascular endothelial growth factor (VEGF)‐A, VEGF‐B, VEGF‐C, and VEGF‐D in the adenoma–carcinoma sequence during colorectal cancer progression , 2003, The Journal of pathology.

[85]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[86]  C. Erlichman.  Fluorouracil and leucovorin for metastatic colorectal cancer. , 1990, Journal of chemotherapy.

[87]  Jeffrey W. Clark,et al.  Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. , 2010, The Lancet. Oncology.

[88]  R. Berardi,et al.  Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[89]  E. Perez,et al.  RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Franklin Peale,et al.  Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. , 2007, Cancer cell.